Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus

Vaccine

Volumn 27, Issue 39, 2009, Pages 5357-5362

  Zuccotti, Gian Vincenzo ^a   Scaramuzza, Andrea ^a   Riboni, Sara ^a   Mameli, Chiara ^a   Pariani, Elena ^b   Tanzi, Elisabetta ^b   Zanetti, Alessandro ^b   Radaelli, Giovanni ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Diabetes mellitus; Immunogenicity; Influenza vaccine; Reactogenicity; Virosomal

Indexed keywords

INFLUENZA VACCINE; VIROSOME VACCINE;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECCHYMOSIS; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; IRRITABILITY; ITALY; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SHIVERING; SIDE EFFECT; SKIN INDURATION; SKIN REDNESS; SWELLING; VOMITING;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PROSPECTIVE STUDIES; VACCINES, VIROSOME; YOUNG ADULT;

EID: 68349112593     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.082     Document Type: Article

References (52)

1. CDC (Centers for Disease Control and Prevention). Prevention & Control of Influenza-Recommendations of the Advisory Committee on Immunization Practices (ACIP) 2008. MMWR 2008; 57(RR07):1-60. Available at http://www.cdc.gov/mmwr/pdf/rr/rr5707.pdf.
2. Bueving H.J., van der Wouden J.C., Berger M.Y., and Thomas S. Incidence of influenza and associated illness in children aged 0-19 years: a systematic review. Rev Med Virol 15 (2005) 383-391
3. Beyer W.E.P., Palache A.M., Baljet M., and Masurel N. Antibody induction by influenza vaccines in elderly: a review of the literature. Vaccine 7 (1989) 385-394
4. Glezen W.P., Greenberg S.B., Atmar R.L., Piedra P.A., and Couch R.B. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 283 (2000) 499-505
5. Barker W.H. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970-78. Am J Public Health 76 (1986) 761-765
6. Barker W.H., and Mullooly J.P. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 112 (1980) 798-811
7. Mullooly J.P., Bridges C.B., Thompson W.W., Chen J., Weintraub E., Jackson L.A., et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine 25 (2007) 846-855
8. O'Brien M.A., Uyeki T.M., Shay D.K., Thompson W.W., Kleinman K., McAdam A., et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics 113 (2004) 585-593
9. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 (2003) 179-186
10. World Health Organization (WHO). Influenza vaccines. Recommendations for the use of inactivated influenza vaccines and other preventive measures. Weekly Epidem Rec 2000:75:281-8. Available at http://www.who.int/wer.
11. Ryan J., Zoellner Y., Gradl B., Palache B., and Medema J. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 24 (2006) 6812-6822
12. Oncel S., Turhan O., Huseyin P.H., and Yalcin A.N. Status of influenza vaccination in patients presenting to two neighbourhood primary health care clinics in Antalya. Infez Med 16 (2008) 74-79
13. World Health Organization (WHO). Influenza vaccines. Weekly Epidem Rec 2002:77:281-9. Available at http://www.who.int/wer.
14. Demicheli V., Rivetti D., Deeks J.J., and Jefferson T.O. Vaccines for preventing influenza in healthy adults. Cochrane Database Sys Rev 3 (2004) CD001269
15. Govaert T.M., Sprenger M.J., Dinant G.J., Aretz K., Masurel N., and Knottnerus J.A. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 12 (1994) 1185-1189
16. Gross P.A., Hermogenes A.W., Sacks H.S., Lau J., and Levandowski R.A. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 123 (1995) 518-527
17. Nicholson KG. Limitations of currently available influenza vaccines. In: WHO. Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses. World Health Organization, Geneva, Switzerland, February 26-27, 2004. p. 26-36. Available at http://www.who.int/vaccine_research/documents/Report_Feb_04.pdf.
18. Jefferson T. Influenza vaccination: policy versus evidence. BMJ 333 (2006) 912-915
19. Mischler R., and Metcalfe I.C. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 20 Suppl. 5 (2002) B17-B23
20. Cryz S.J., Que J.U., and Gluck R. A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response inhumans. Vaccine 14 (1996) 1381-1383
21. Moser C., Metcalfe I.C., and Viret J.F. Virosomal adjuvanted antigen delivery systems. Expert Rev Vaccines 2 (2003) 189-196
22. Moser C., Amacker M., Kammer A.R., Rasi S., Westerfeld N., and Zurbriggen R. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccines 6 (2007) 711-721
23. De Bruijn I.A., Nauta J., Gerez L., and Palache A.M. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res 103 (2004) 139-145
24. ®) in elderly subjects. Vaccine 24 (2006) 6629-6631
25. De Bruijn I.A., Nauta J., Cramer W.C., Gerez L., and Palache A.M. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 23 Suppl. 1 (2005) S39-S44
26. Kanra G., Marchisio P., Feiterna-Sperling C., Gaedicke G., Lazar H., Durrer P., et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 23 (2004) 300-306
27. Schaad U.B., Buhlmann U., Burger R., Ruedeberg A., Wilder-Smith, Rutishauser M., et al. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother 44 (2000) 1163-1167
28. Zuccotti G.V., Cucchi C., Sala D., and Giovannini M. Immunogenicity and safety of a virosomal influenza vaccine in HIV-infected children. Acta Paediatr 91 (2002) 486-487
29. Herzog C., Metcalfe I.C., and Schaad U.B. Virosome influenza vaccine in children. Vaccine 20 Suppl. 5 (2002) B24-B28
30. Salleras L., Dominguez A., Pumarola T., Prat A., Marcos M.A., Garrido P., et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study. Vaccine 24 (2006) 6638-6642
31. Zuccotti G.V., Amendola A., Viganò A., Pariani E., Zappa A., Pogliani L., et al. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with astma. Vaccine 25 (2007) 6692-6698
32. Pozzilli P., Gale E.A., Visalli N., Baroni M., Crovari P., Frighi V., et al. The immune response to influenza vaccination in diabetic patients. Diabetologia 29 (1986) 850-854
33. Diepersloot R.J., Bouter K.P., Beyer W.E., Hoekstra J.B., and Masurel M. Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitus. Diabetologia 30 (1987) 397-401
34. Ruben F.L., Fireman P., Laporte R.E., Drash A.L., Uhrin M., and Vergona R. Immune response to killed influenza vaccine in patients with type 1 diabetes: altered responses associated with HLADRS and 4. J Lab Clin Med 112 (1988) 595-602
35. Feery B.J., Hartman L.J., Hampson A.W., and Proietto J. Influenza immunization in adults with diabetes mellitus. Diabetes Care 6 (1983) 475-478
36. El-Madhun A.S., Cox R.J., Seime A., Sovik O., and Haaheim L.R. Systemic and local immune response after parenteral influenza vaccination in juvenile diabetic and healthy controls: results prom a pilot study. Vaccine 16 (1998) 156-160
37. Diepersloot R.J., Bouter K.P., van Beek R., Lucas C.J., Masurel N., and Erkelens D.W. Cytotoxic T-cell response to influenza a subunit vaccine in patients with type 1 diabetes mellitus. Neth J Med 35 (1989) 68-75
38. World Health Organization (WHO). Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses. World Health Organization, Geneva, Switzerland, February 26-27, 2004. Available at http://www.who.int/vaccine_research/documents/Report_Feb_04.pdf.
39. Smith S.A., and Poland G.A. American diabetes association. Influenza and pneumococcal immunization in diabetes. Diabetes Care 27 Suppl. 1 (2004) S111-S113
40. Karthikeyan A., and Agwu J.C. Uptake of influenza vaccination among children with diabetes -a re-audit. J Infect 56 (2008) 158-159
41. CDC (Centers for Disease Control and Prevention). Prevention & Control of Influenza-Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR 2007; 56(RR06):1-54. Available at http://www.cdc.gov/mmwr/pdf/rr/rr5606.pdf.
42. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical Practice (E6-R1). Available at http://www.ich.org/LOB/media/MEDIA482.pdf.
43. Larsen M.L., Hørder M., and Mogensen E.F. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N Engl J Med 323 (1990) 1021-1025
44. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
45. Palmer D.F., Dowdle W.R., Coleman M.T., and Schild G.C. Advanced laboratory technicals for immunological diagnostic. Immunology ser. nr. 6. procedural guide. Part 2. Haemagglutination-inhibition test (1975), U.S. Dept Health. Ed. Welfare, P.H.S, Atlanta p. 25-62
46. Committee for Proprietary of Medicinal Product (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. The European Agency for the Evaluation of Medicinal Products. CPMP/BWP/214/96, London, March 12, 1997. Available at http://www.emea.eu.int/pdfs/human/bwp/021496en.pdf.
47. Valle L., Amicizia D., Bacilieri S., Banfi F., Riente R., Durando P., et al. Performance testing of two new one-step real time PCR assays for detection of human influenza and avian influenza viruses isolated in humans and respiratory syncytial virus. J Prev Med Hyg 47 (2006) 127-133
48. Looijmans-Van den Akker I., Verheij T.J., Buskens E., Nichol K.L., Rutten G.E., and Hak E. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care 29 (2006) 1771-1776
49. Potter C.W. A history of influenza. J Appl Microbiol 91 (2001) 572-579
50. Beyer W.E.P., Palache A.M., Sprenger M.J.W., Hendriksen E., Tukker J.J., Darioli R., et al. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine 14 (1996) 1331-1339
51. Beyer W.E., Palache A.M., and Osterhaus A.D. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Investig 15 (1998) 1-12
52. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A.M., et al. The virosome concept for influenza vaccines. Vaccine 23 Suppl. 1 (2005) S26-S38